Lindahl Richard S.'s most recent trade in Emergent Biosolutions Inc was a trade of 2,733 Common Stock done at an average price of $6.6 . Disclosure was reported to the exchange on June 8, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Emergent Biosolutions Inc | Richard S. Lindahl | EVP, Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.63 per share. | 08 Jun 2025 | 2,733 | 296,492 (0%) | 0% | 6.6 | 18,120 | Common Stock |
| Emergent Biosolutions Inc | Richard S. Lindahl | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2025 | 178,546 | 484,490 | - | - | Employee Stock Options (Right to Buy) | |
| Emergent Biosolutions Inc | Richard S. Lindahl | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2025 | 146,888 | 299,225 (0%) | 0% | 0 | Common Stock | |
| Emergent Biosolutions Inc | Richard S. Lindahl | EVP, Chief Financial Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 12 Feb 2025 | 16,916 | 154,093 (0%) | 0% | 0 | Common Stock | |
| Emergent Biosolutions Inc | Richard S. Lindahl | EVP, Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.48 per share. | 12 Feb 2025 | 1,073 | 153,020 (0%) | 0% | 7.5 | 8,026 | Common Stock |
| Emergent Biosolutions Inc | Richard S. Lindahl | EVP, Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.48 per share. | 12 Feb 2025 | 683 | 152,337 (0%) | 0% | 7.5 | 5,109 | Common Stock |
| Compass Therapeutics Inc | Richard S. Lindahl | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2025 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| Emergent Biosolutions Inc | Richard S. Lindahl | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Oct 2024 | 15,000 | 171,009 (0%) | 0% | 0 | Common Stock | |
| Emergent Biosolutions Inc | Richard S. Lindahl | EVP, Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.19 per share. | 08 Jun 2024 | 2,733 | 156,009 (0%) | 0% | 6.2 | 16,917 | Common Stock |
| Emergent Biosolutions Inc | Richard S. Lindahl | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Mar 2024 | 125,000 | 305,944 | - | - | Employee Stock Options (Right to Buy) | |
| Emergent Biosolutions Inc | Richard S. Lindahl | EVP, Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.23 per share. | 29 Feb 2024 | 9,037 | 159,426 (0%) | 0% | 3.2 | 29,190 | Common Stock |
| Emergent Biosolutions Inc | Richard S. Lindahl | EVP, Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.39 per share. | 29 Feb 2024 | 684 | 158,742 (0%) | 0% | 3.4 | 2,319 | Common Stock |
| Emergent Biosolutions Inc | Lindahl Richard S. | EVP, Chief Financial Officer | Sale or transfer of securities back to the company at price $ 2.71 per share. | 21 Feb 2024 | 4,012 | 168,980 (0%) | 0% | 2.7 | 10,873 | Common Stock |
| Emergent Biosolutions Inc | Lindahl Richard S. | EVP, Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.74 per share. | 21 Feb 2024 | 517 | 168,463 (0%) | 0% | 2.7 | 1,417 | Common Stock |
| Compass Therapeutics Inc | Richard S. Lindahl | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2024 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| Emergent Biosolutions Inc | Richard S. Lindahl | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2023 | 49,231 | 180,944 | - | - | Employee Stock Option (Right to buy) | |
| Emergent Biosolutions Inc | Richard S. Lindahl | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2023 | 49,231 | 172,992 (0%) | 0% | 0 | Common Stock | |
| Emergent Biosolutions Inc | Richard S. Lindahl | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2023 | 24,616 | 123,761 (0%) | 0% | 0 | Common Stock | |
| Emergent Biosolutions Inc | Richard S. Lindahl | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2023 | 12,308 | 93,049 | - | - | Employee Stock Options (Right to Buy) | |
| Emergent Biosolutions Inc | Richard S. Lindahl | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2023 | 12,308 | 99,145 (0%) | 0% | 0 | Common Stock | |
| Emergent Biosolutions Inc | Richard S. Lindahl | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2023 | 6,154 | 86,837 (0%) | 0% | 0 | Common Stock | |
| Emergent Biosolutions Inc | Richard S. Lindahl | EVP, Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.38 per share. | 28 Feb 2023 | 1,074 | 16,906 (0%) | 0% | 12.4 | 13,296 | Common Stock |
| Emergent Biosolutions Inc | Richard S. Lindahl | EVP, Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.71 per share. | 23 Feb 2023 | 977 | 17,980 (0%) | 0% | 13.7 | 13,395 | Common Stock |
| Emergent Biosolutions Inc | Richard S. Lindahl | EVP, Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.30 per share. | 23 Feb 2023 | 444 | 18,957 (0%) | 0% | 14.3 | 6,349 | Common Stock |
| Emergent Biosolutions Inc | Richard S. Lindahl | EVP, Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.25 per share. | 08 Feb 2023 | 2,396 | 19,401 (0%) | 0% | 13.3 | 31,747 | Common Stock |
| Emergent Biosolutions Inc | Richard S. Lindahl | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2023 | 101 | 21,797 (0%) | 0% | 0 | Common Stock | |
| Emergent Biosolutions Inc | Richard S. Lindahl | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2022 | 38,664 | 38,664 | - | - | Employee Stock Options (Right to Buy) | |
| Emergent Biosolutions Inc | Richard S. Lindahl | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2022 | 31,417 | 69,375 (0%) | 0% | 0 | Common Stock | |
| Emergent Biosolutions Inc | Richard S. Lindahl | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2022 | 16,916 | 86,291 (0%) | 0% | 0 | Common Stock | |
| Emergent Biosolutions Inc | Richard S. Lindahl | EVP, Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 39.64 per share. | 28 Feb 2022 | 818 | 85,473 (0%) | 0% | 39.6 | 32,426 | Common Stock |
| Emergent Biosolutions Inc | Richard S. Lindahl | EVP, Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 42.47 per share. | 23 Feb 2022 | 983 | 37,958 (0%) | 0% | 42.5 | 41,748 | Common Stock |
| Emergent Biosolutions Inc | Richard S. Lindahl | EVP, Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 42.23 per share. | 23 Feb 2022 | 516 | 38,941 (0%) | 0% | 42.2 | 21,791 | Common Stock |
| Emergent Biosolutions Inc | Richard S. Lindahl | EVP, Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 42.23 per share. | 22 Feb 2022 | 2,298 | 39,457 (0%) | 0% | 42.2 | 97,045 | Common Stock |
| Emergent Biosolutions Inc | Richard S. Lindahl | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2022 | 1,836 | 41,755 (0%) | 0% | 0 | Common Stock | |
| Emergent Biosolutions Inc | Richard S. Lindahl | EVP, Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 37.46 per share. | 15 Nov 2021 | 3,000 | 39,919 (0%) | 0% | 37.5 | 112,380 | Common Stock |
| Emergent Biosolutions Inc | Richard S. Lindahl | EVP, Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 61.62 per share. | 08 May 2021 | 1,054 | 36,919 (0%) | 0% | 61.6 | 64,947 | Common Stock |
| Emergent Biosolutions Inc | Richard S. Lindahl | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2021 | 16,043 | 16,043 | - | - | Employee Stock Options (Right to Buy) | |
| Emergent Biosolutions Inc | Richard S. Lindahl | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2021 | 4,012 | 39,802 (0%) | 0% | 0 | Common Stock | |
| Emergent Biosolutions Inc | Richard S. Lindahl | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2021 | 4,011 | 35,790 (0%) | 0% | 0 | Common Stock | |
| Emergent Biosolutions Inc | Richard S. Lindahl | EVP, Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 93.49 per share. | 24 Feb 2021 | 1,010 | 38,792 (0%) | 0% | 93.5 | 94,425 | Common Stock |
| Emergent Biosolutions Inc | Richard S. Lindahl | EVP, Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 97.15 per share. | 24 Feb 2021 | 819 | 37,973 (0%) | 0% | 97.2 | 79,566 | Common Stock |
| Emergent Biosolutions Inc | Richard S. Lindahl | EVP, Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 123.45 per share. | 09 Feb 2021 | 2,522 | 31,779 (0%) | 0% | 123.5 | 311,341 | Common Stock |
| Emergent Biosolutions Inc | Richard S. Lindahl | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2021 | 2,495 | 34,301 (0%) | 0% | 0 | Common Stock |